Edition:
United Kingdom

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

13.31USD
18 Jan 2019
Change (% chg)

$-4.78 (-26.42%)
Prev Close
$18.09
Open
$11.87
Day's High
$13.56
Day's Low
$11.57
Volume
7,689,777
Avg. Vol
813,261
52-wk High
$27.32
52-wk Low
$11.57

Latest Key Developments (Source: Significant Developments)

Immunomedics Receives Complete Response Letter From FDA For Sacituzumab Govitecan Biologics License Application
Friday, 18 Jan 2019 

Jan 17 (Reuters) - Immunomedics Inc ::IMMUNOMEDICS RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR SACITUZUMAB GOVITECAN BIOLOGICS LICENSE APPLICATION.IMMUNOMEDICS -CO GOING TO REQUEST MEETING WITH FDA AS SOON AS POSSIBLE TO GAIN FULL UNDERSTANDING OF AGENCY'S REQUIREMENTS AND TIMELINES FOR APPROVAL.WILL WORK CLOSELY WITH FDA WITH GOAL OF BRINGING MEDICINE TO PATIENTS AS SOON AS POSSIBLE.  Full Article

Johnson Matthey Partners With Immunomedics To Develop Cancer Treatment
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - Johnson Matthey::JOHNSON MATTHEY PLC - CO PARTNERS WITH IMMUNOMEDICS TO DEVELOP CANCER TREATMENT.JOHNSON MATTHEY PLC - MANUFACTURING PARTNERSHIP IS FOR LARGE-SCALE PRODUCTION OF THE DRUG-LINKER USED IN IMMUNOMEDICS’ LEAD ANTIBODY-DRUG CONJUGATE.  Full Article

Immunomedics Enters Exchange Agreements With Outstanding 4.75 pct Convertible Note Holders
Wednesday, 3 Oct 2018 

Oct 3 (Reuters) - Immunomedics Inc ::IMMUNOMEDICS-ON OCT 2, ENTERED INTO EXCHANGE AGREEMENTS WITH LIMITED NUMBER OF HOLDERS OF OUTSTANDING 4.75% CONVERTIBLE SENIOR NOTES DUE 2020.IMMUNOMEDICS INC - COMPANY ANTICIPATES THE EXCHANGES WILL BE COMPLETED ON OR ABOUT OCTOBER 5, 2018 - SEC FILING.IMMUNOMEDICS - UPON COMPLETION OF EXCHANGES, AGGREGATE AMOUNT OF CONVERTIBLE NOTES IS EXPECTED TO BE REDUCED TO ABOUT $7.1 MILLION.IMMUNOMEDICS INC - UPON COMPLETION OF EXCHANGES, AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE NOTES IS EXPECTED TO BE REDUCED TO ABOUT $7.1 MILLION.IMMUNOMEDICS-AGREED TO EXCHANGE ABOUT $12.9 MILLION CONVERTIBLE NOTES HELD BY NOTEHOLDERS FOR ABOUT 2.57 MILLION NEWLY ISSUED SHARES OF CO'S COMMON STOCK.  Full Article

Immunomedics And Samsung Biologics Announce Strategic Manufacturing Partnership
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Samsung Biologics Co Ltd <207940.KS>::IMMUNOMEDICS AND SAMSUNG BIOLOGICS ANNOUNCE STRATEGIC MANUFACTURING PARTNERSHIP.IMMUNOMEDICS INC - TECHNOLOGY TRANSFER AND ENGINEERING RUNS FOR NEW ANTIBODY PRODUCTION ARE CURRENTLY UNDERWAY.IMMUNOMEDICS INC - COMMERCIAL PRODUCTION EXPECTED TO BEGIN IN 2020 UNDER PARTNERSHIP.IMMUNOMEDICS - SAMSUNG WILL MANUFACTURE CO'S ' PROPRIETARY HUMANIZED ANTIBODY, HRS7, AT ITS MANUFACTURING FACILITIES IN INCHEON, SOUTH KOREA.  Full Article

Immunomedics Says CFO Michael Garone Resigned
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - Immunomedics Inc ::SAYS CFO MICHAEL GARONE RESIGNED.SAYS USAMA MALIK APPOINTED INTERIM CFO.APPOINTED WILLIAM FRICKER, TO SERVE AS COMPANY'S PRINCIPAL ACCOUNTING OFFICER.SAYS GARONE SHALL REMAIN THE COMPANY’S VICE PRESIDENT, FINANCE, UNTIL MAY 18, 2019 - SEC FILING.  Full Article

Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. FDA
Monday, 21 May 2018 

May 21 (Reuters) - Immunomedics Inc ::IMMUNOMEDICS SUBMITS BIOLOGICS LICENSE APPLICATION FOR SACITUZUMAB GOVITECAN TO THE U.S. FOOD AND DRUG ADMINISTRATION.IMMUNOMEDICS INC - FILING IS BASED ON PHASE 1/2 DATA OF SACITUZUMAB GOVITECAN IN MTNBC.  Full Article

Immunomedics Reports Q3 Loss Per Share $0.21
Wednesday, 9 May 2018 

May 9 (Reuters) - Immunomedics Inc ::IMMUNOMEDICS ANNOUNCES THIRD QUARTER FISCAL 2018 RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.21.Q3 EARNINGS PER SHARE VIEW $-0.15 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE $500,000 VERSUS $1.3 MILLION.Q3 REVENUE VIEW $4.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Immunomedics Inc ::IMMUNOMEDICS AND ROYALTY PHARMA ANNOUNCE ROYALTY FUNDING AND STOCK PURCHASE AGREEMENTS TOTALLING $250 MILLION.IMMUNOMEDICS INC - ROYALTY PHARMA ACQUIRES ROYALTY RIGHTS ON GLOBAL NET SALES OF SACITUZUMAB GOVITECAN (IMMU-132) ACROSS ALL INDICATIONS FOR $175 MILLION.IMMUNOMEDICS INC - ROYALTY PHARMA HAS ALSO PURCHASED $75 MILLION IN COMMON STOCK OF IMMUNOMEDICS, AT $17.15 PER SHARE.IMMUNOMEDICS - TRANSACTION WILL PROVIDE SUFFICIENT CASH TO FUND OPERATIONS INTO 2020.  Full Article

Immunomedics announces first quarter fiscal results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Immunomedics Inc :Immunomedics announces first quarter fiscal 2018 results and provides corporate update.Q1 loss per share $0.97.Q1 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Immunomedics Inc - qtrly ‍total revenue was $0.7 million for both quarters ended September 30, 2017 and September 30, 2016​.  Full Article

Immunomedics reports Q4 loss per share $0.48
Wednesday, 16 Aug 2017 

Aug 16 (Reuters) - Immunomedics Inc :Immunomedics announces fiscal 2017 results and strategic developments; reiterates guidance on bla submission timeline.Q4 revenue fell 33 percent to $600,000.Q4 revenue view $2.3 million -- Thomson Reuters I/B/E/S.Q4 loss per share $0.48.Q4 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Immunomedics Inc - ‍cash, cash equivalents, and marketable securities totaled $154.9 million as of june 30, 2017​.Immunomedics Inc - ‍company expects to present final results of IMMU-132 in mtnbc that will form basis of bla submission later this year​.Immunomedics Inc - ‍believe that current financial resources are sufficient to support operations through september 2018​.  Full Article

Immunomedics' cancer treatment fails to win accelerated approval from the FDA

Jan 17 Immunomedics Inc said on Thursday the U.S. Food and Drug Administration declined to grant accelerated approval for its breast cancer treatment, sacituzumab.